Brief: Tarsus Pharmaceuticals Q2 EPS USD -0.43
06/08/2026 12:04
BRIEF-Tarsus Pharmaceuticals Q2 EPS USD -0.43 Aug 06 (Reuters) - Tarsus Pharmaceuticals Q2 operating expenses USD 193.82 million.
- Q2 net income USD -18.551 million
- Q2 product sales USD 173.912 million vs. IBES estimate USD 169.7 million
- Q2 basic EPS USD -0.43
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)